Activating ROCK1 somatic mutations in human cancer

Oncogene

Volumn 29, Issue 17, 2010, Pages 2591-2598

  Lochhead, P A ^a,b   Wickman, G ^a   Mezna, M ^a   Olson, M F ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b BABRAHAM INSTITUTE   (United Kingdom)

Author keywords

Actin; Cancer; Cytoskeleton; Kinase; Rho; ROCK

Indexed keywords

RHO KINASE; RHO KINASE 1; UNCLASSIFIED DRUG;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CYTOSKELETON; ENZYME ACTIVITY; HUMAN; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; SOMATIC MUTATION;

CYTOSKELETON; HUMANS; MUTATION; NEOPLASMS; RHO-ASSOCIATED KINASES;

EID: 77951880868     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.3     Document Type: Article

References (24)

1. Abe H, Kamai T, Tsujii T, Nakamura F, Mashidori T, Mizuno T et al. (2008). Possible role of the RhoC/ROCK pathway in progression of clear cell renal cell carcinoma. Biomed Res 29: 155-161.
2. Benitah SA, Valeron PF, van Aelst L, Marshall CJ, Lacal JC. (2004). Rho GTPases in human cancer: an unresolved link to upstream and downstream transcriptional regulation. Biochim Biophys Acta 1705: 121-132.
3. Bokoch GM. (1998). Caspase-mediated activation of PAK2 during apoptosis: proteolytic kinase activation as a general mechanism of apoptotic signal transduction? Cell Death Differ 5: 637-645.
4. Coleman ML, Sahai EA, Yeo M, Bosch M, Dewar A, Olson MF. (2001). Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. Nat Cell Biol 3: 339-345.
5. Doki Y, Shiozaki H, Tahara H, Inoue M, Oka H, Iihara K et al. (1993). Correlation between E-cadherin expression and invasiveness in vitro in a human esophageal cancer cell line. Cancer Res 53: 3421-3426.
6. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G et al. (2007). Patterns of somatic mutation in human cancer genomes. Nature 446: 153-158.
7. Ishizaki T, Naito M, Fujisawa K, Maekawa M, Watanabe N, Saito Y et al. (1997). p160ROCK, a Rho-associated coiled-coil forming protein kinase, works downstream of Rho and induces focal adhesions. FEBS Lett 404: 118-124.
8. Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T, Narumiya S. (1999). An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med 5: 221-225.
9. Jacobs M, Hayakawa K, Swenson L, Bellon S, Fleming M, Taslimi P et al. (2006). The structure of dimeric rock i reveals the mechanism for ligand selectivity. J Biol Chem 281: 260-268.
10. Kamai T, Arai K, Sumi S, Tsujii T, Honda M, Yamanishi T et al. (2002). The rho/rho-kinase pathway is involved in the progression of testicular germ cell tumour. BJU Int 89: 449-453.
11. Kamai T, Tsujii T, Arai K, Takagi K, Asami H, Ito Y et al. (2003). Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res 9: 2632-2641.
12. Kamai T, Yamanishi T, Shirataki H, Takagi K, Asami H, Ito Y et al. (2004). Overexpression of RhoA, Rac1, and Cdc42 GTPases is associated with progression in testicular cancer. Clin Cancer Res 10: 4799-4805.
13. Matsui T, Amano M, Yamamoto T, Chihara K, Nakafuku M, Ito M et al. (1996). Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J 15: 2208-2216.
14. Nakajima M, Hayashi K, Egi Y, Katayama K, Amano Y, Uehata M et al. (2003). Effect of Wf-536, a novel ROCK inhibitor, against metastasis of B16 melanoma. Cancer Chemother Pharmacol 52: 319-324.
15. Narumiya S, Tanji M, Ishizaki T. (2009). Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Rev 28: 65-76.
16. Ogawa T, Tashiro H, Miyata Y, Ushitora Y, Fudaba Y, Kobayashi T et al. (2007). Rho-associated kinase inhibitor reduces tumor recurrence after liver transplantation in a rat hepatoma model. Am J Transplant 7: 347-355.
17. Olson MF, Sahai E. (2009). The actin cytoskeleton in cancer cell motility. Clin Exp Metastasis 26: 273-287.
18. Sahai E, Marshall CJ. (2002). RHO-GTPases and cancer. Nat Rev Cancer 2: 133-142.
19. Sebbagh M, Hamelin J, Bertoglio J, Solary E, Breard J. (2005). Direct cleavage of ROCK II by granzyme B induces target cell membrane blebbing in a caspase-independent manner. J Exp Med 201: 465-471.
20. Somlyo AV, Bradshaw D, Ramos S, Murphy C, Myers CE, Somlyo AP. (2000). Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem Biophys Res Commun 269: 652-659.
21. Tan I, Seow KT, Lim L, Leung T. (2001). Intermolecular and intramolecular interactions regulate catalytic activity of myotonic dystrophy kinase-related Cdc42-binding kinase {alpha}. Mol Cell Biol 21: 2767-2778.
22. Wen W, Liu W, Yan J, Zhang M. (2008). Structure basis and unconventional lipid membrane binding properties of the PH-C1 tandem of Rho kinases. J Biol Chem 283: 26263-26273.
23. Xue F, Takahara T, Yata Y, Xia Q, Nonome K, Shinno E et al. (2008). Blockade of Rho/Rho-associated coiled coil-forming kinase signaling can prevent progression of hepatocellular carcinoma in matrix metalloproteinase-dependent manner. Hepatol Res 38: 810-817.
24. Ying H, Biroc SL, Li WW, Alicke B, Xuan JA, Pagila R et al. (2006). The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol Cancer Ther 5: 2158-2164.